Added to YB: 2025-04-23
Pitch date: 2025-04-20
NVO [bullish]
Novo Nordisk A/S
-18.17%
current return
Author Info
Capitalist Letters simplifies investing and makes it understandable for everybody. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 375.66
Price Target
118.00 (-62%)
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
growth
Novo Nordisk: Easy Double From Here?
NVO: Dominant in diabetes/weight-loss drugs with superior pipeline vs Eli Lilly despite timing disadvantage. Weight-loss market to grow 5x by 2030 ($100B+). Rock-solid balance sheet with industry-leading margins (85% gross/30% ROIC). Phenomenal 20% 5yr earnings growth at bargain 14x forward P/E.
Read full article (13 min)